Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus (177)lutetium-prostate specific membrane antigen-617 (Lu-177-PSMA-617) in the LuPARP trial
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要